Literature DB >> 20229157

[Treatment of hypertension in diabetic patients].

Jörg Slany1.   

Abstract

Hypertension, diabetes and visceral adiposity are very common co-morbidities with an exceedingly high risk of cardiovascular and renal complications. Therefore, emphatic treatment is necessary. Blood pressure goal is recommended below 130/80 mmHg with office measurements, and less than 7 out of 30 values below 135/85 mmHg with home measurements. Strict blood pressure control reduces macro- and microvascular morbidity. Usually combination of different drugs is necessary to achieve a satisfactory blood pressure control. First line should be an inhibitor of the RAS, commonly combined with a calcium channel blocker and/or a diuretic. Fixed-dose combinations are recommended. If indicated or necessary, newer generation betablockers may be given as an adjunct. Life style measures and active reduction of further risk factors are essential.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20229157     DOI: 10.1007/s10354-010-0743-z

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  20 in total

1.  Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).

Authors:  Lars Rydén; Eberhard Standl; Małgorzata Bartnik; Greet Van den Berghe; John Betteridge; Menko-Jan de Boer; Francesco Cosentino; Bengt Jönsson; Markku Laakso; Klas Malmberg; Silvia Priori; Jan Ostergren; Jaakko Tuomilehto; Inga Thrainsdottir; Ilse Vanhorebeek; Marco Stramba-Badiale; Peter Lindgren; Qing Qiao; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; John Camm; Veronica Dean; Jaap Deckers; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; João Morais; Ady Osterspey; Juan Tamargo; José Luis Zamorano; Jaap W Deckers; Michel Bertrand; Bernard Charbonnel; Erland Erdmann; Ele Ferrannini; Allan Flyvbjerg; Helmut Gohlke; Jose Ramon Gonzalez Juanatey; Ian Graham; Pedro Filipe Monteiro; Klaus Parhofer; Kalevi Pyörälä; Itamar Raz; Guntram Schernthaner; Massimo Volpe; David Wood
Journal:  Eur Heart J       Date:  2007-01       Impact factor: 29.983

2.  Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus.

Authors:  Ian H de Boer; Bryan Kestenbaum; Tessa C Rue; Michael W Steffes; Patricia A Cleary; Mark E Molitch; John M Lachin; Noel S Weiss; John D Brunzell
Journal:  Arch Intern Med       Date:  2008-09-22

3.  Masked hypertension, urinary albumin excretion rate, and echocardiographic parameters in putatively normotensive type 2 diabetic patients.

Authors:  Cristiane B Leitão; Luís H Canani; Caroline K Kramer; Juliana C Boza; Antônio F Pinotti; Jorge L Gross
Journal:  Diabetes Care       Date:  2007-02-15       Impact factor: 19.112

4.  Blood pressure and risk of type 2 diabetes mellitus in men and women from the general population: the Monitoring Trends and Determinants on Cardiovascular Diseases/Cooperative Health Research in the Region of Augsburg Cohort Study.

Authors:  Christa Meisinger; Angela Döring; Margit Heier
Journal:  J Hypertens       Date:  2008-09       Impact factor: 4.844

5.  Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients.

Authors:  A L M Vlek; Y van der Graaf; W Spiering; F L J Visseren
Journal:  J Hum Hypertens       Date:  2008-02-14       Impact factor: 3.012

6.  Masked nocturnal hypertension--a novel marker of risk in type 2 diabetes.

Authors:  M Wijkman; T Länne; J Engvall; T Lindström; C J Ostgren; F H Nystrom
Journal:  Diabetologia       Date:  2009-04-25       Impact factor: 10.122

7.  Lowering blood pressure reduces renal events in type 2 diabetes.

Authors:  Bastiaan E de Galan; Vlado Perkovic; Toshiharu Ninomiya; Avinesh Pillai; Anushka Patel; Alan Cass; Bruce Neal; Neil Poulter; Stephen Harrap; Carl-Erik Mogensen; Mark Cooper; Michel Marre; Bryan Williams; Pavel Hamet; Giuseppe Mancia; Mark Woodward; Paul Glasziou; Diederick E Grobbee; Stephen MacMahon; John Chalmers
Journal:  J Am Soc Nephrol       Date:  2009-02-18       Impact factor: 10.121

8.  Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.

Authors:  Lars H Lindholm; Hans Ibsen; Knut Borch-Johnsen; Michael Hecht Olsen; Kristian Wachtell; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristianson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan M Edelman; Steven Snapinn
Journal:  J Hypertens       Date:  2002-09       Impact factor: 4.844

9.  Effect of a multifactorial intervention on mortality in type 2 diabetes.

Authors:  Peter Gaede; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

Review 10.  The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis.

Authors:  Daphne P Guh; Wei Zhang; Nick Bansback; Zubin Amarsi; C Laird Birmingham; Aslam H Anis
Journal:  BMC Public Health       Date:  2009-03-25       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.